metformin has been researched along with linagliptin in 81 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.23) | 29.6817 |
| 2010's | 59 (72.84) | 24.3611 |
| 2020's | 21 (25.93) | 2.80 |
| Authors | Studies |
|---|---|
| Dugi, KA; Graefe-Mody, EU; Padula, S; Ring, A; Withopf, B | 1 |
| Dugi, KA; Forst, T; Friedrich, C; Graefe-Mody, U; Herbach, K; Ring, A; Uhlig-Laske, B; Woerle, HJ | 1 |
| Dugi, KA; Kubiak, R; Patel, S; Rosenstock, J; Tamminen, I; Taskinen, MR; Woerle, HJ | 1 |
| Dugi, KA; Owens, DR; Swallow, R; Woerle, HJ | 1 |
| Jermendy, G | 2 |
| Scheen, AJ | 4 |
| Derosa, G; Maffioli, P | 1 |
| Elrod, S; Harrington, C; McLaughlin-Middlekauff, J; Singh-Franco, D | 2 |
| Haak, T; Jones, R; Meinicke, T; von Eynatten, M; Weber, S; Woerle, HJ | 2 |
| Paquot, N; Scheen, AJ | 1 |
| Bhattacharya, S; Dugi, KA; Gallwitz, B; Patel, S; Rauch, T; Rosenstock, J; von Eynatten, M; Woerle, HJ | 1 |
| Deeks, ED | 1 |
| Christensen, M; Knop, FK | 1 |
| Barnett, AH; Harper, R; Patel, S; Thiemann, S; Toorawa, R; von Eynatten, M; Woerle, HJ | 1 |
| Doupis, J; Koliaki, C | 1 |
| Haak, T | 1 |
| Bakris, GL; Flynn, C | 1 |
| Gong, Y; Inagaki, N; Kagimura, T; Murai, M; Patel, S; Watada, H; Woerle, HJ | 1 |
| Gong, Y; Tong, N; Woerle, HJ; Yan, S; Yang, JK; Zeng, Z; Zhang, X | 1 |
| Bhattacharya, S; Durán-Garcia, S; Patel, S; Pinnetti, S; Rosenstock, J; Thiemann, S; Woerle, HJ; Yki-Järvinen, H | 1 |
| Scheen, AJ; Van Gaal, LF | 1 |
| Anastassiadis, E; Diessel, S; Forst, T; Löffler, A; Pfützner, A | 1 |
| Buschke, S; Friedrich, C; Meinicke, T; Metzmann, K; Ring, A | 1 |
| Friedrich, C; Hohl, K; Jungnik, A; Meinicke, T; Metzmann, K; Ring, A; Schnell, D; Theodor, R | 1 |
| Bajaj, M; Gilman, R; Kempthorne-Rawson, J; Lewis-D'Agostino, D; Patel, S; Woerle, HJ | 1 |
| Bailes, Z; Caballero, AE; Del Prato, S; Gallwitz, B; Lewis-D'Agostino, D; Patel, S; Ross, SA; Thiemann, S; von Eynatten, M; Woerle, HJ | 2 |
| Broedl, UC; DeFronzo, RA; Kaste, R; Lewin, A; Liu, D; Patel, S; Woerle, HJ | 1 |
| Duval, V; Friedrich, C; Graefe-Mody, U; Jaehde, U; Patel, S; Retlich, S; Staab, A | 1 |
| Gong, Y; Izumoto, T; Ning, G; Patel, S; Wang, W; Yang, G; Yang, J; Zhang, C | 1 |
| Byrne, FM; Chapman, V; Cheetham, S; Vickers, S | 1 |
| Bailes, Z; Ji, J; Ji, L; Patel, S; Seck, T; Thiemann, S; Zinman, B | 1 |
| Crowe, S; McGill, JB; von Eynatten, M; Woerle, HJ; Yki-Järvinen, H | 1 |
| Cui, Y; Friedrich, C; Hohl, K; Meinicke, T; Pichereau, S; Zhao, S; Zhao, X | 1 |
| Durán-Garcia, S; Hehnke, U; Lee, J; Patel, S; Rosenstock, J; Thiemann, S; Woerle, HJ; Yki-Järvinen, H | 1 |
| Cai, B; D'Souza, AO; Raju, A; Shetty, S | 1 |
| Jang, HB; Jeon, JY; Kim, MG; Kim, SY; Lim, CH; Moon, SJ | 1 |
| Broedl, UC; Gallwitz, B; Götz, S; Maldonado-Lutomirsky, M; Nordaby, M; Tinahones, FJ; Woerle, HJ | 1 |
| Hirose, T; Iga, R; Kanda, E; Kobayashi, Y; Kumashiro, N; Miyagi, M; Shigiyama, F; Uchino, H | 1 |
| Du, J; Fan, B; Gong, Y; Hehnke, U; Liu, J; Ma, J; Mu, Y; Pan, C; Wang, X; Zhang, X; Zhang, Y | 1 |
| Berk, A; Chilton, R; Esmaeili, H; Jax, T; Marx, N; Stirban, A; Terjung, A; Thiemann, S; von Eynatten, M | 1 |
| Ihana-Sugiyama, N; Kakei, M; Noda, M; Sugiyama, T; Tsujimoto, T; Yamamoto-Honda, R | 1 |
| Lingvay, I | 1 |
| Jain, RK | 1 |
| González-Heredia, T; González-Ortiz, M; Hernández-Corona, DM; Martínez-Abundis, E | 1 |
| Abdalla, OM; Abdel-Megied, AM; Saad, AS; Soliman, SS | 1 |
| DeFronzo, RA; Kohler, S; Lee, C | 1 |
| Fawzy, MG; Mahrouse, MA; Moussa, BA | 2 |
| Bergman, R; Kridin, K | 1 |
| Nishimura, R; Takahashi, H; Tsujino, D; Utsunomiya, K | 1 |
| Abdullah, AM; Fakhre, NA; M Amin, KF | 1 |
| Bhutani, R; Bodla, RB; Kant, R; Kapoor, G | 1 |
| Li, XX; Tai, GJ; Xu, M; Zhang, WX | 1 |
| Araki, E; Miyamoto, Y; Sakamoto, W; Tanaka, Y; Unno, Y | 1 |
| Bosch, A; Bramlage, P; Jung, S; Kannenkeril, D; Karg, MV; Ott, C; Schmieder, RE; Striepe, K | 1 |
| Aguilar-García, A; Álvarez-Canales, M; Angulo-Romero, F; Durán-Pérez, EG; Evia-Viscarra, ML; Farfán-Vázquez, D; Folli, F; Guardado-Mendoza, R; Jiménez-Ceja, LM; Martínez-López, YE; Montes de Oca-Loyola, ML; Salazar-López, SS; Suárez-Pérez, EL | 1 |
| Ferrannini, E; Katsiki, N; Mazidi, M; Ofori-Asenso, R | 1 |
| Acosta, T; Alkandari, A; Boukichou Abdelkader, N; Colagiuri, S; Djordjevic, P; Egido, J; Gabriel, R; Gilis-Januszewska, A; Gómez-Huelgas, R; Kamenov, Z; Lalic, N; Lind, M; Lindström, J; López-Ridaura, R; Makrilakis, K; Mitrakou, A; Natali, A; Pastor, JC; Paulweber, B; Satman, I; Silva, L; Teuschl, Y; Tuomilehto, J | 1 |
| Beetz, N; Bertulis, J; Lang, B; Lee, J; Lingvay, I; Lippert, C; Loley, C; Manning, LS; Schuler-Metz, A; Sennewald, R; Terada, D | 1 |
| Ahmadi, N; Amdur, RL; Awal, HB; Brichacek, B; Domingues, CC; Dore, FJ; Elzarki, A; Fakhri, M; Fosso, M; Kundu, N; Nandula, SR; Safai, S; Sen, S | 1 |
| Danser, AHJ; Hartmann, B; Holst, JJ; Joles, JA; Kramer, MHH; Muskiet, MHA; Ouwens, DM; Smits, MM; Tonneijck, L; Touw, DJ; van Raalte, DH | 1 |
| Alegete, P; Boodida, S; Vankalapati, KR | 1 |
| Hashiguchi, Y; Hosoyamada, K; Imamura, N; Kajiya, S; Kamada, T; Komorizono, Y; Koriyama, N; Shinmaki, H; Tsukasa, M; Ueyama, N | 1 |
| Anumolu, PD; Cvs, S; Gurrala, S; Raj, S | 1 |
| Bosch, A; Bramlage, P; Jung, S; Kannenkeril, D; Kolwelter, J; Korn, M; Ott, C; Schiffer, M; Schmieder, RE; Striepe, K | 1 |
| Cai, ZJ; Chen, T; Li, N; Lin, WQ; Liu, MB; Zheng, B | 1 |
| Chenchula, S; Padmavathi, R; Varthya, SB | 1 |
| Abbas, NS; Derayea, SM; Mohamed, YAS; Omar, MA; Saleh, GA | 1 |
| Aragona, M; Daniele, G; Dardano, A; Del Prato, S; Miccoli, R | 1 |
| Barkatestrong/Strong, H; Khaladkar, K; Mohan, B; Suryawanshi, S | 1 |
| Nirwan, N; Vohora, D | 1 |
| Feng, Y; Ge, Y; He, Y; Hou, L; Huo, M; Ji, Y; Li, H; Liu, X; Liu, Y; Luo, Q; Qian, F; Wang, J; Wei, Y; Wu, S; Wu, Y; Xue, F; Yu, Y | 1 |
| Atonal-Flores, B; Barranco-Juarez, A; León-Vázquez, ML | 1 |
17 review(s) available for metformin and linagliptin
| Article | Year |
|---|---|
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Metformin; Nitriles; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Tablets; Treatment Outcome; Triazoles; Vildagliptin | 2011 |
Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
Topics: Area Under Curve; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Glyburide; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Pioglitazone; Purines; Quinazolines; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain | 2012 |
Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Purines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Vildagliptin | 2012 |
The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Topics: Aged; Biomarkers; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Pioglitazone; Purines; Quinazolines; Randomized Controlled Trials as Topic; Thiazolidinediones; Treatment Outcome; United States | 2012 |
Linagliptin: a review of its use in the management of type 2 diabetes mellitus.
Topics: Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Linagliptin; Metformin; Purines; Quinazolines; Treatment Outcome | 2012 |
Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Purines; Quinazolines | 2012 |
Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Practice Guidelines as Topic; Purines; Quinazolines | 2012 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Evaluation; Drug Interactions; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Purines; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Efficacy and safety of Jentadueto® (linagliptin plus metformin).
Topics: Animals; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Purines; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
[Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Purines; Quinazolines | 2013 |
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Piperidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uracil | 2017 |
Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Treatment Outcome | 2020 |
Rationality, Efficacy, Tolerability of Empagliflozin Plus Linagliptin Combination for the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Observational Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 2; Exenatide; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Metformin; Network Meta-Analysis; Sitagliptin Phosphate | 2022 |
42 trial(s) available for metformin and linagliptin
| Article | Year |
|---|---|
Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
Topics: Adult; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Young Adult | 2009 |
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2010 |
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Young Adult | 2011 |
Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds; Treatment Outcome; Young Adult | 2011 |
Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2012 |
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Research Design; Sulfonylurea Compounds; Treatment Failure; Treatment Outcome | 2012 |
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds; Treatment Outcome | 2012 |
Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes.
Topics: Asian People; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Treatment Outcome | 2013 |
Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.
Topics: Aged; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Placebos; Purines; Quinazolines; Sulfonylurea Compounds | 2013 |
Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Male; Metformin; Middle Aged; Pioglitazone; Purines; Quinazolines; Retrospective Studies; Thiazolidinediones; Treatment Outcome | 2013 |
Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2013 |
Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Linagliptin; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Postprandial Period; Proinsulin; Purines; Quinazolines; Risk Factors; Sulfonylurea Compounds | 2014 |
Linagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tablets.
Topics: Adult; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Prospective Studies; Purines; Quinazolines; Tablets; Therapeutic Equivalency | 2014 |
Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.
Topics: Adult; Area Under Curve; Biological Availability; Cross-Over Studies; Drug Combinations; Female; Food-Drug Interactions; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Solubility; Tablets | 2014 |
Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Pioglitazone; Purines; Quinazolines; Thiazolidinediones; Treatment Failure; Treatment Outcome; Weight Gain | 2014 |
Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; International Cooperation; Linagliptin; Metformin; Purines; Quinazolines; Treatment Outcome | 2015 |
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome; Weight Loss | 2015 |
Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Nonlinear Dynamics | 2015 |
Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Treatment Outcome | 2016 |
Efficacy and safety of linagliptin co-administered with low-dose metformin once daily versus high-dose metformin twice daily in treatment-naïve patients with type 2 diabetes: a double-blind randomized trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Treatment Outcome | 2015 |
Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
Topics: Aged; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Male; Metformin; Middle Aged; Pioglitazone; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2015 |
Relative bioavailability study of linagliptin/metformin tablets in healthy Chinese subjects.
Topics: Administration, Oral; Adult; Area Under Curve; Asian People; Biological Availability; China; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Female; Half-Life; Healthy Volunteers; Humans; Hypoglycemic Agents; Linagliptin; Male; Metabolic Clearance Rate; Metformin; Purines; Quinazolines; Tablets; Young Adult | 2015 |
Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Kidney Function Tests; Linagliptin; Male; Metformin; Middle Aged; Racial Groups | 2016 |
Phase 1 and Pharmacokinetic Drug-Drug Interaction Study of Metformin, Losartan, and Linagliptin Coadministered With DW1029M in Healthy Volunteers.
Topics: Adult; Area Under Curve; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Healthy Volunteers; Humans; Linagliptin; Losartan; Male; Metformin; Middle Aged; Morus; Plant Extracts; Pueraria; Young Adult | 2017 |
Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Pancreatitis; Reproductive Tract Infections; Treatment Outcome; Urinary Tract Infections | 2017 |
Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Prospective Studies; Treatment Outcome | 2017 |
Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naïve Asian patients with type 2 diabetes.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Tablets; Treatment Outcome | 2017 |
A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
Topics: Aged; Biomarkers; Brachial Artery; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Microcirculation; Microvessels; Middle Aged; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Vasodilation | 2017 |
Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Humans; Hypoglycemic Agents; Inositol; Insulin; Insulin, Long-Acting; Isoindoles; Linagliptin; Male; Metformin; Middle Aged; Postprandial Period | 2017 |
Effect of Linagliptin Versus Metformin on Glycemic Variability in Patients with Impaired Glucose Tolerance.
Topics: Adult; Blood Glucose; Blood Glucose Self-Monitoring; Double-Blind Method; Female; Glucose Intolerance; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged | 2017 |
Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Treatment Outcome | 2018 |
Which is better, high-dose metformin monotherapy or low-dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low-dose metformin monotherapy? A randomized,
Topics: Biomarkers; Blood Glucose; Blood Glucose Self-Monitoring; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Glycemic Index; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Prognosis | 2019 |
Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial.
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Linagliptin; Male; Metformin; Middle Aged | 2019 |
Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.
Topics: Aged; Arterial Pressure; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Germany; Glucosides; Humans; Insulin Glargine; Linagliptin; Male; Metformin; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness | 2020 |
The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial.
Topics: Adult; Aged; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Life Style; Linagliptin; Male; Metformin; Middle Aged; Treatment Outcome | 2020 |
Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data.
Topics: Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Double-Blind Method; Europe; Female; Galvanic Skin Response; Humans; Hyperglycemia; International Cooperation; Life Style; Linagliptin; Male; Metformin; Microcirculation; Middle Aged; Patient Selection; Research Design; Risk Factors | 2020 |
Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
Topics: Adolescent; Adult; Area Under Curve; Benzhydryl Compounds; Cross-Over Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Male; Medication Adherence; Metformin; Middle Aged; Therapeutic Equivalency; Young Adult | 2020 |
Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial.
Topics: Adult; Aged; Antigens, CD34; Biomarkers; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; District of Columbia; Double-Blind Method; Drug Therapy, Combination; Endothelial Progenitor Cells; Female; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Male; Metformin; Middle Aged; Pilot Projects; Receptors, CXCR4; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2020 |
Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial.
Topics: Adult; Aged; Chemokine CXCL12; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Kidney; Linagliptin; Male; Metformin; Middle Aged; Natriuresis; Overweight; Sulfonylurea Compounds; Treatment Outcome | 2020 |
Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Non-alcoholic Fatty Liver Disease; Purines; Quinazolines; Treatment Outcome | 2021 |
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Germany; Glomerular Filtration Rate; Glucosides; Hemodynamics; Humans; Hypoglycemic Agents; Insulin Glargine; Linagliptin; Male; Metformin; Middle Aged; Prospective Studies; Renal Plasma Flow; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2021 |
Efficacy and Safety of a Fixed Dose Combination of Remogliflozin Etabonate and Vildagliptin in Patients with Type-2 Diabetes Mellitus: A Randomized, Active-Controlled, Double-Blind, Phase III Study.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Prospective Studies; Pyrazoles; Treatment Outcome; Vildagliptin | 2022 |
22 other study(ies) available for metformin and linagliptin
| Article | Year |
|---|---|
Gliptin versus a sulphonylurea as add-on to metformin.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Purines; Quinazolines; Sulfonylurea Compounds | 2012 |
Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Purines; Quinazolines; Sulfonylurea Compounds | 2012 |
Response letter. Effects of linagliptin.
Topics: Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Postprandial Period; Purines; Quinazolines; Respiratory System; Weight Gain; Weight Loss | 2012 |
Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments.
Topics: Animal Feed; Animals; Behavior, Animal; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-Fat; Glial Fibrillary Acidic Protein; Hypoglycemic Agents; Insulin; Linagliptin; Male; Metformin; Microscopy, Fluorescence; Neuroglia; Neurons; Pain; Pain Management; Pain Measurement; Pioglitazone; PPAR gamma; Purines; Quinazolines; Rats; Rats, Sprague-Dawley; Thiazolidinediones | 2015 |
Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes.
Topics: Aged; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Male; Metformin; Middle Aged; Treatment Outcome; Weight Gain; Weight Loss | 2016 |
Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy.
Topics: Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Health Care Costs; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Linagliptin; Male; Metformin; Middle Aged; Propensity Score; Sulfonylurea Compounds | 2016 |
Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Simultaneous spectrophotometric determination of compounds having relatively disparate absorbance and concentration ranges; application to antidiabetic formulation of linagliptin and metformin.
Topics: Hypoglycemic Agents; Linagliptin; Metformin; Reference Standards; Reproducibility of Results; Spectrophotometry | 2018 |
Different resolution techniques for management of overlapped spectra: Application for the determination of novel co-formulated hypoglycemic drugs in their combined pharmaceutical dosage form.
Topics: Benzhydryl Compounds; Canagliflozin; Drug Combinations; Glucosides; Hypoglycemic Agents; Limit of Detection; Linagliptin; Linear Models; Metformin; Reproducibility of Results; Spectrophotometry, Ultraviolet; Tablets | 2018 |
Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
Topics: Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Eruptions; Eosinophils; Female; Humans; Hypoglycemic Agents; Israel; Leukocyte Count; Linagliptin; Male; Metformin; Mucous Membrane; Pemphigoid, Bullous; Retrospective Studies; Risk Assessment; Sex Factors; Vildagliptin | 2018 |
Mean centering-triple divisor and ratio derivative-zero crossing for simultaneous determination of some diabetes drugs in their quaternary mixture with severely overlapping spectra.
Topics: Algorithms; Analysis of Variance; Benzhydryl Compounds; Glucosides; Hypoglycemic Agents; Linagliptin; Metformin; Pioglitazone; Spectrophotometry, Ultraviolet; Tablets | 2019 |
Optimization of a single HPLC-PDA method for quantifying Metformin, Gliclazide, Pioglitazone, Dapagliflozin, Empagliflozin, Saxagliptin, Linagliptin and Teneligliptin using central composite design.
Topics: Adamantane; Benzhydryl Compounds; Chromatography, High Pressure Liquid; Dipeptides; Dose-Response Relationship, Drug; Gliclazide; Glucosides; Linagliptin; Metformin; Molecular Structure; Pioglitazone; Pyrazoles; Software; Structure-Activity Relationship; Thiazolidines | 2019 |
Inhibition of neointima hyperplasia by the combined therapy of linagliptin and metformin via AMPK/Nox4 signaling in diabetic rats.
Topics: AMP-Activated Protein Kinases; Animals; Aorta, Thoracic; Carotid Arteries; Constriction, Pathologic; Diabetes Mellitus, Experimental; Endothelium, Vascular; Flow Cytometry; Hyperplasia; Linagliptin; Male; Metformin; Muscle, Smooth, Vascular; NADPH Oxidase 4; NADPH Oxidases; Neointima; Oxygen; Rats; Rats, Sprague-Dawley; RNA Interference; Signal Transduction; Vascular Remodeling; Vasoconstriction; Wound Healing | 2019 |
In brief: Trijardy XR - a new 3-drug combination for Type 2 diabetes.
Topics: Administration, Oral; Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Metformin | 2020 |
Stability-indicating ultra performance liquid chromatography method development and validation for simultaneous estimation of metformin, linagliptin, and empagliflozin in bulk and pharmaceutical dosage form.
Topics: Benzhydryl Compounds; Chromatography, High Pressure Liquid; Drug Stability; Glucosides; Hypoglycemic Agents; Limit of Detection; Linagliptin; Linear Models; Metformin; Reproducibility of Results; Tablets | 2021 |
Quality-by-Design Approach for Chromatographic Analysis of Metformin, Empagliflozin and Linagliptin.
Topics: Benzhydryl Compounds; Chromatography, High Pressure Liquid; Glucosides; Limit of Detection; Linagliptin; Metformin; Reproducibility of Results | 2022 |
Application of experimental design in HPLC method optimization and robustness for the simultaneous determination of canagliflozin, empagliflozin, linagliptin, and metformin in tablet.
Topics: Benzhydryl Compounds; Canagliflozin; Chromatography, High Pressure Liquid; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Limit of Detection; Linagliptin; Linear Models; Metformin; Reproducibility of Results; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Tablets | 2021 |
Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.
Topics: Adamantane; China; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Humans; Linagliptin; Metformin; Middle Aged; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil; Vildagliptin | 2021 |
Micellar Thin Layer Chromatography and Computer-Aided Analysis of Empagliflozin, Linagliptin and Metformin HCl Ternary Mixture.
Topics: Chromatography, Thin Layer; Computers; Linagliptin; Metformin; Micelles; Polysorbates; Surface-Active Agents | 2022 |
Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glucose; Glycated Hemoglobin; Heart Disease Risk Factors; HIV Infections; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Linagliptin; Metformin; Middle Aged; Quality of Life; Recombinant Fusion Proteins; Risk Factors; Sepsis | 2022 |
Linagliptin in Combination With Metformin Ameliorates Diabetic Osteoporosis Through Modulating BMP-2 and Sclerostin in the High-Fat Diet Fed C57BL/6 Mice.
Topics: Animals; Biomarkers; Body Weight; Calcium; Cytokines; Diabetes Mellitus, Experimental; Diet, High-Fat; Glucose; Insulin; Leptin; Linagliptin; Metformin; Mice; Mice, Inbred C57BL; Osteocalcin; Osteoporosis | 2022 |
[Indicators of diabetes mellitus after liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Longitudinal Studies; Male; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2023 |